https://nxtin.health/2026/10/12/cardiovascular-screening-at-bial-identifies-previously-unknown-risk-factors-in-four-out-of-ten-participants/ 2026-10-12T11:39:43Z NXTin health en Cardiovascular screening at Bial identifies previously unknown risk factors in four out of ten participants 2026-10-12T11:39:41Z Blog https://nxtin.health/2026/10/12/fresenius-acquires-remaining-45-of-mabxience-for-up-to-e750-million-taking-full-ownership-of-its-biosimilars-platform/ 2026-10-12T08:40:15Z NXTin health en Fresenius acquires remaining 45% of mAbxience for up to €750 million, taking full ownership of its biosimilars platform 2026-10-12T08:40:13Z Blog https://nxtin.health/2026/10/12/theramex-agrees-to-license-european-rights-to-investigational-cervical-precancer-treatment/ 2026-10-12T08:34:36Z NXTin health en Theramex agrees to license European rights to investigational cervical precancer treatment 2026-10-12T08:34:34Z Blog https://nxtin.health/2026/10/12/mayors-from-60-cities-commit-to-local-action-as-heat-and-climate-related-deaths-rise-across-europe/ 2026-10-12T08:16:45Z NXTin health en Mayors from 60 cities commit to local action as heat and climate-related deaths rise across Europe 2026-10-12T08:15:51Z Blog https://nxtin.health/2026/10/12/european-commission-earmarks-e65m-to-safeguard-critical-data-for-life-sciences-and-biotechnology/ 2026-10-12T08:17:29Z NXTin health en European Commission earmarks €65M to safeguard critical data for life sciences and biotechnology 2026-10-12T08:08:24Z Blog https://nxtin.health/2026/10/11/orano-med-inaugurates-europes-first-industrial-facility-dedicated-to-the-production-of-lead-212-based-targeted-alpha-therapies/ 2026-10-12T06:57:40Z NXTin health en Orano Med inaugurates Europe’s first industrial facility dedicated to the production of lead-212-based targeted alpha therapies 2026-10-11T19:00:37Z Blog https://nxtin.health/2026/10/11/u-porto-inovacao-invests-e60000-in-research-innovation-and-proof-of-concept-projects/ 2026-10-12T11:33:24Z NXTin health en U.Porto Inovação invests €60,000 in research innovation and proof-of-concept projects 2026-10-11T18:47:16Z Blog https://nxtin.health/2026/10/11/spectacell-secures-e6-million-to-accelerate-drug-development-and-improve-immune-therapies/ 2026-10-12T11:22:04Z NXTin health en SpectaCell secures €6 million to accelerate drug development and improve immune therapies 2026-10-11T18:29:05Z Blog https://nxtin.health/2026/10/11/sanofi-and-regeneron-expand-global-alliance-with-multiple-next-generation-long-acting-immunology-antibodies/ 2026-10-11T19:09:17Z NXTin health en Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies 2026-10-11T15:01:00Z Blog https://nxtin.health/2026/10/10/cori-clinical-raises-4m-to-help-clinical-teams-design-better-trials-and-reduce-costly-delays/ 2026-10-10T18:19:14Z NXTin health en Cori Clinical raises $4M to help clinical teams design better trials and reduce costly delays 2026-10-10T18:19:11Z Blog https://nxtin.health/2026/10/10/sava-raises-36m-series-b-and-signs-european-deal-with-ascensia-for-its-next-generation-glucose-microsensor/ 2026-10-10T06:09:01Z NXTin health en Sava raises $36M Series B and signs European deal with Ascensia for its next-generation glucose microsensor 2026-10-10T06:08:59Z Blog